Kathleen Tregoning - 26 Dec 2023 Form 4 Insider Report for Cerevel Therapeutics Holdings, Inc.

Role
Title: Chief Corporate Affairs Officer
Signature
/s/ Mark Bodenrader, as Attorney-in-Fact
Issuer symbol
N/A
Transactions as of
26 Dec 2023
Net transactions value
+$31,658
Form type
4
Filing time
28 Dec 2023, 16:15:11 UTC
Previous filing
21 Dec 2023
Next filing
04 Jan 2024
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction CERE Common Stock Options Exercise $31,658 +3,150 +42% $10.05 10,666 26 Dec 2023 Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction CERE Stock Option (Right to Buy) Options Exercise $0 -3,150 -1.2% $0.000000 255,082 26 Dec 2023 Common Stock 3,150 $10.05 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 25% of the shares subject to this option vested and became exercisable on July 28, 2021, with the remainder vesting in thirty-six (36) equal monthly installments thereafter.

Remarks:

Title: Chief Corporate Affairs Officer